Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 September 2019Website:
http://igmbio.comNext earnings report:
07 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:02:05 GMTDividend
Analysts recommendations
Institutional Ownership
IGMS Latest News
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.04 per share a year ago.
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IGM Biosciences (IGMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $1.43 per share a year ago.
IGM Biosciences (IGMS) has the perfect mix of factors that could lead to better-than-expected earnings in its upcoming report. Be sure to have the key expectations in mind.
IGM Biosciences (IGMS) has been upgraded to a Zacks Rank #2 (Buy), indicating increased confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.19 per share a year ago.
The average of price targets set by Wall Street analysts indicates a potential upside of 63.1% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The consensus price target hints at a 35.1% upside potential for IGM Biosciences, Inc. (IGMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.
- 1(current)
What type of business is IGM Biosciences?
IGM Biosciences, Inc. is an American biopharmaceutical company specializing in the discovery and development of new drugs based on the engineering of IgM antibodies (antibodies naturally produced by the human immune system) for the treatment of oncological diseases. The company has been in operation since 1993 and is based in Mountain View, California. Candidate drugs: IGM-2323 IgM antibody targeting T-cells for the treatment of patients with non-Hodgkin's lymphoma. IGM-8444 and IGM-7354 antibodies being investigated for the treatment of patients with solid and hematologic malignancies. The company has developed and patented its own technological platform for antibody engineering. Additionally, the company is conducting preclinical studies of drugs for the treatment of acute myeloid leukemia and multiple myeloma.
What sector is IGM Biosciences in?
IGM Biosciences is in the Healthcare sector
What industry is IGM Biosciences in?
IGM Biosciences is in the Biotechnology industry
What country is IGM Biosciences from?
IGM Biosciences is headquartered in United States
When did IGM Biosciences go public?
IGM Biosciences initial public offering (IPO) was on 18 September 2019
What is IGM Biosciences website?
https://igmbio.com
Is IGM Biosciences in the S&P 500?
No, IGM Biosciences is not included in the S&P 500 index
Is IGM Biosciences in the NASDAQ 100?
No, IGM Biosciences is not included in the NASDAQ 100 index
Is IGM Biosciences in the Dow Jones?
No, IGM Biosciences is not included in the Dow Jones index
When was IGM Biosciences the previous earnings report?
No data
When does IGM Biosciences earnings report?
The next expected earnings date for IGM Biosciences is 07 March 2025